A SPECIALIST IN PSYCHIATRIC AND NEUROLOGICAL DISORDERS
Who are Lundbeck?
• Lundbeck are specialists in mental health. We develop new treatments from the point of discovering a new molecule, all the way through the development process to regulatory approval, manufacture and distribution
• We are committed to research and development of new pharmaceuticals, and reinvest around 20% of all our revenue into R&D
• We have discovered, developed, manufactured and distributed several medications used every day in the UK to treat people living with depression, schizophrenia, Alzheimer’s disease or Parkinson’s disease
• Our medicines are currently used by over 65,000 patients living with psychological and neurological disorders in the UK
• The Lundbeck Foundation owns 70% of the shares of Lundbeck, and annually distributes around £61m in research grants each year*
• We invest in developing tools and resources that can support the NHS and social care organisations. These materials include the Impact of Depression Resource and Impact of Schizophrenia Resource
• We work with NHS organisations across the UK, to support local NHS objectives and improvements in the care and management of patients suffering from brain disease
• We are always open to working in partnership to improve the lives of patients; our specialism in mental health means we are able to support a holistic, whole pathway approach to improving the care of patients with psychiatric and neurological disorders
*https://www.lundbeck.com/global/about-us/facts-and-background (Accessed March 2020)
Lundbeck Ltd. have provided sponsorship of the exhibition WiFi and have had no other involvement in the meeting or its organisation.
